Korglutide

Korglutide is a next-generation oral peptide composed of 7 amino acids, developed by Caregen as a nutraceutical solution for weight management and metabolic balance. Designed for once-daily intake, it offers a convenient and non-invasive approach aligned with the global shift toward preventive and lifestyle-oriented health solutions.
As an oral product, Korglutide provides a practical alternative for consumers seeking effective weight management without the complexity of injectable approaches, supporting ease of use and long-term adherence. As a food supplement, it goes beyond simple weight reduction by supporting body composition improvement, particularly through targeted fat reduction and metabolic balance.
Notably, Korglutide has completed the U.S. FDA New Dietary Ingredient (NDI) notification in January 2026, reinforcing its safety profile and supporting its positioning as a globally compliant and scientifically validated ingredient.

Clinical Results

• In a randomized, double-blind, placebo-controlled Phase III study in obese individuals (BMI ≥ 30) and overweight individuals with type 2 diabetes (BMI ≥ 27), Korglutide demonstrated significant improvements across key metabolic parameters. Body weight decreased by -10.78% (-9.3 kg), BMI by -10.83%, HbA1c by -10.98%, WHR by -5.21%, and body fat mass by -20.71% (-7.0 kg), while skeletal muscle mass reduction remained limited to -0.75% (-0.27 kg), indicating fat reduction with minimized muscle loss. (Muscle ratio increased by 11.40%).
•   A second Phase III study in non-obese individuals including NWO (Normal Weight Obesity) showed -8.02% (-5.2 kg) reduction in body weight and -8.26% reduction in BMI, with body fat decreased by -9.6% and visceral fat level reduced by -9.21%, supporting improved body composition beyond simple weight loss.

These results indicate that Korglutide supports fat reduction while preserving lean mass across both obese and non-obese populations, positioning it not only as a weight management solution but also as a body recomposition and metabolic wellness product.
Korglutide addresses key consumer segments including overweight and obese individuals, those with central or visceral fat accumulation, and NWO populations. It is also highly relevant for young, health-conscious consumers—particularly females—focused on body shape and fat reduction, as well as individuals seeking to maintain outcomes following weight management programs.
With a structured 12-week usage protocol, Korglutide enables predictable consumption patterns and scalable commercialization. Compared to conventional supplements that often lack clear differentiation, it offers a clinically supported, convenient solution aligned with the growing demand for non-invasive, preventive, and lifestyle-driven health management.